Nine Questions to Ask Any Peptide Provider

You can assess a peptide clinic in one conversation. Nine questions, asked plainly, and paying more attention to how they are answered than to what the answer is.

Most people evaluating a clinic look at the website, the credentials on the about page, and the price. None of those tell you much. What does is asking direct questions and listening to the texture of the response — whether the person answering knows the framework they are operating in, and whether they are comfortable saying they don't know something. Ask these by phone, by email, or in the consultation itself. Write the answers down.

1. Is what you are proposing FDA-approved, and if so for what indication?

A good answer is direct. Either the product is FDA-approved for a specific indication and they name it, or it is not approved and they say so plainly — possibly adding that it is being prescribed off-label, or that it is a compounded preparation, both of which are legitimate things to say. Off-label prescribing is lawful and routine in medicine, and a provider explaining that distinction clearly is doing their job.

A bad answer avoids the word "approved" while implying it. "It's pharmaceutical grade." "It's completely legal." "It's fully compliant." "It comes from an FDA-registered facility" — registration is not approval, and that sentence is deployed specifically because it sounds like it is. Any answer that treats the question as pedantic is telling you they would rather you had not asked. The distinction is explained in our article on the peptide regulatory picture.

2. What is its regulatory basis, and where does it sit on FDA's bulk substance lists?

This is the technical follow-up and it separates the informed from the rest.

A good answer engages with the framework: whether the substance is compounded, whether it appears on the relevant 503A or 503B bulk drug substance list, whether it is under evaluation, and whether the position has changed recently. A provider might say that availability shifted because FDA moved a substance into the category it has identified as raising significant safety risks, and that they consequently stopped offering it. That answer, even when it is bad news, is the best sign you will get.

A bad answer is blankness, or irritation, or a claim that the lists are bureaucratic noise. Several widely discussed research peptides sit in exactly the category FDA has flagged, and a provider who does not know where their product sits does not know whether they should be offering it.

3. Which pharmacy prepares it, and how is that pharmacy licensed?

A good answer names the pharmacy, states which state licenses it, and says whether it operates as a 503A compounding pharmacy or a 503B outsourcing facility. It should also confirm the pharmacy is licensed in your state, which is a requirement people forget to check. A provider comfortable with this answers immediately, because there is nothing to hide.

A bad answer is "a licensed US pharmacy" with no name, "our partner pharmacy", or a refusal on the basis of proprietary relationships. Where the medicine going into your body is made is not a trade secret. If they will not name it, you cannot verify anything, and the possibility that it is not a pharmacy at all is one you cannot rule out. The alternative — products from outside the pharmacy system entirely — is covered in the research peptide grey market.

4. Does a licensed clinician take a full medical history before anything is prescribed?

A good answer describes a real consultation: a clinician, licensed in your state, reviewing your conditions, your full medication and supplement list, allergies, family history and previous treatments — and doing so before deciding what, if anything, is appropriate. They should be able to tell you the clinician's name and licence details.

A bad answer is a web form followed by an approval. If the process consists of ticking boxes and paying, no clinical decision is being made. Interactions and contraindications only get identified if someone asks about them, and the questions that matter are frequently ones you would not think to volunteer.

5. What monitoring is included, and what happens if the results change?

A good answer is specific: which baseline tests are done, at what intervals they are repeated, who reviews them, how you are told the results, and — critically — what specific findings would cause them to reduce or stop treatment. That last part is the tell. A provider who has thought about monitoring has thought about what would make them stop.

A bad answer is that monitoring is not necessary because the compound is well tolerated. For products with limited human data, "well tolerated" cannot be a claim anyone is entitled to make — the studies that would establish it have not been done. Absence of reported problems in a population nobody is monitoring is not reassurance.

6. What happens if I have an adverse effect?

A good answer describes a process: who to contact, within what timeframe, whether there is out-of-hours cover, what happens if you need to be seen in person, and how they handle a situation requiring care beyond what a remote service can provide. They should also say that adverse effects are reported to FDA's MedWatch system, and be able to explain how.

A bad answer is "call us" with no detail, or a support email address, or a suggestion that you see your own doctor — a doctor who does not know what you were given and did not prescribe it. A service that will prescribe but will not manage the consequences has kept the profitable half of medicine and discarded the rest.

7. What does the evidence in humans actually show?

A good answer is more varied than you might expect, and three quite different responses are all acceptable. They may cite a specific study and describe its size, design and limitations. They may say that the human evidence is limited or preclinical, explain what that means, and let you decide. They may say they don't know offhand and offer to send you the references.

A bad answer is fluent confidence with nothing underneath. "Studies show." "It's been used for decades." "The research is very promising." "Thousands of our patients have had great results." If you ask for a citation and receive a link to another clinic's blog post, you have your answer. How to evaluate what they send you is covered in our article on separating peptide evidence from marketing.

Also listen for outcome promises. Any provider guaranteeing a result is making a claim they cannot support, and for most of these compounds no such claim is supportable by anyone.

8. How does the fee work, and does it depend on the outcome?

A good answer is that you pay for the consultation, and the clinician's decision does not affect what you pay. Medication, if prescribed, is billed separately by the pharmacy or clearly itemised. You are told the full cost before committing, including monitoring. Cancellation terms are stated.

A bad answer is any structure where the fee is contingent on approval, or where a single price bundles consultation and product so that a decision not to treat costs the business money. That arrangement gives the person making the clinical decision a financial stake in one particular answer. Watch also for automatic renewal, long minimum commitments, and quantity discounts that reward taking more — none of which belong in a clinical relationship. The same pattern in other contexts is described in how to spot a prescription mill.

9. Under what circumstances would you tell me not to do this?

Save this one for last. It is the most useful question on the list.

A good answer is immediate and concrete. Specific conditions that rule someone out. Specific medications. Situations where they would refer rather than treat. A frank statement that a proportion of enquiries end without a prescription, and roughly what proportion. A clinician who has genuinely turned people away can describe the last time they did it.

A bad answer is hesitation, or a vague gesture at safety, or the suggestion that it is suitable for nearly everyone. Every real medical intervention has people it is wrong for. A provider unable to name any is not screening — and if nobody is ever declined, the assessment is decorative.

Using the list

You do not need all nine answered perfectly. You are looking for a pattern. A provider who answers the first three cleanly usually answers the rest well, and one who deflects on the first three has told you what you need to know before you reach the fourth.

Honest uncertainty is a good sign. "The human evidence for that is thin and I'd want you to understand that before we discuss it" is the answer of someone practising medicine. Certainty about compounds that have never been properly tested is the answer of someone selling something.

Broader guidance on judging a remote practice is in what telehealth is actually good for and what it isn't. Our peptide therapy page sets out how we approach this area, and you are welcome to put all nine questions to us when you book a consultation — including the ninth. A consultation is an assessment, not a purchase.